{"id":"NCT00718237","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","officialTitle":"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2008-07-18","resultsPosted":"2010-07-23","lastUpdate":"2017-04-13"},"enrollment":762,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus","Gastroenteritis"],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)","otherNames":["RotaTeq™","V260"]},{"type":"BIOLOGICAL","name":"Comparator: Comparator: Placebo (unspecified)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate whether V260 is effective and well tolerated in Japanese healthy infants.","primaryOutcome":{"measure":"Number of Participants With Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","timeFrame":"At least 14 days following the 3rd vaccination","effectByArm":[{"arm":"RotaTeq™","deltaMin":7,"sd":null},{"arm":"Placebo","deltaMin":27,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23732903"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":380},"commonTop":["Diarrhoea","Nasopharyngitis","Vomiting","Pyrexia","Upper respiratory tract inflammation"]}}